Emergent Cost Of Revenue vs Net Income From Continuing Ops Analysis

EBS Stock

USD 7.27 0.06 0.83%

Emergent Biosolutions financial indicator trend analysis is much more than just examining Emergent Biosolutions latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Emergent Biosolutions is a good investment. Please check the relationship between Emergent Biosolutions Cost Of Revenue and its Net Income From Continuing Ops accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Emergent Biosolutions. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For more information on how to buy Emergent Stock please use our How to Invest in Emergent Biosolutions guide.

Cost Of Revenue vs Net Income From Continuing Ops

Cost Of Revenue vs Net Income From Continuing Ops Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Emergent Biosolutions Cost Of Revenue account and Net Income From Continuing Ops. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Emergent Biosolutions' Cost Of Revenue and Net Income From Continuing Ops is -0.59. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Net Income From Continuing Ops in the same time period over historical financial statements of Emergent Biosolutions, assuming nothing else is changed. The correlation between historical values of Emergent Biosolutions' Cost Of Revenue and Net Income From Continuing Ops is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of Emergent Biosolutions are associated (or correlated) with its Net Income From Continuing Ops. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income From Continuing Ops has no effect on the direction of Cost Of Revenue i.e., Emergent Biosolutions' Cost Of Revenue and Net Income From Continuing Ops go up and down completely randomly.

Correlation Coefficient

-0.59

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Cost Of Revenue

Cost of Revenue is found on Emergent Biosolutions income statement and represents the costs associated with goods and services Emergent Biosolutions provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Net Income From Continuing Ops

Most indicators from Emergent Biosolutions' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Emergent Biosolutions current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Emergent Biosolutions. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For more information on how to buy Emergent Stock please use our How to Invest in Emergent Biosolutions guide.At this time, Emergent Biosolutions' Selling General Administrative is comparatively stable compared to the past year. Issuance Of Capital Stock is likely to gain to about 10.1 M in 2025, whereas Tax Provision is likely to drop slightly above 48.4 M in 2025.

	2022	2023	2024	2025 (projected)
Total Operating Expenses	593.2M	1.0B	1.2B	1.3B
Cost Of Revenue	693.7M	705.4M	811.2M	851.8M

Total Operating Expenses Cost Of Revenue

Emergent Biosolutions fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock
Total Assets		0.86	0.49	0.55	0.93	0.73	0.62	0.42	0.54	0.7	0.74	0.42	0.45	0.7	0.63	0.67	0.77	0.59	0.61	0.71	0.72	0.9	0.64	0.43	0.71	0.7
Short Long Term Debt Total	0.86		0.58	0.83	0.67	0.62	0.9	0.12	0.7	0.5	0.71	0.76	0.39	0.5	0.52	0.7	0.61	0.52	0.8	0.78	0.7	0.99	0.56	0.73	0.75	0.72
Other Current Liab	0.49	0.58		0.66	0.35	0.76	0.49	0.47	0.89	0.39	0.75	0.68	-0.32	0.39	0.6	0.75	0.04	0.68	0.85	0.89	0.06	0.6	0.86	0.41	0.71	0.75
Total Current Liabilities	0.55	0.83	0.66		0.33	0.58	0.78	0.06	0.7	0.36	0.6	0.92	0.07	0.36	0.27	0.57	0.24	0.3	0.82	0.73	0.36	0.76	0.58	0.94	0.61	0.62
Total Stockholder Equity	0.93	0.67	0.35	0.33		0.67	0.37	0.52	0.35	0.79	0.58	0.17	0.52	0.79	0.52	0.45	0.76	0.44	0.43	0.6	0.72	0.74	0.54	0.23	0.49	0.48
Property Plant And Equipment Net	0.73	0.62	0.76	0.58	0.67		0.41	0.79	0.71	0.6	0.92	0.44	-0.23	0.6	0.73	0.78	0.26	0.77	0.73	0.73	0.14	0.65	0.95	0.36	0.79	0.78
Net Debt	0.62	0.9	0.49	0.78	0.37	0.41		-0.19	0.7	0.08	0.62	0.82	0.26	0.08	0.52	0.71	0.46	0.49	0.79	0.61	0.6	0.88	0.36	0.69	0.75	0.72
Retained Earnings	0.42	0.12	0.47	0.06	0.52	0.79	-0.19		0.29	0.63	0.6	-0.11	-0.35	0.63	0.44	0.38	-0.05	0.56	0.21	0.37	-0.21	0.17	0.75	-0.12	0.38	0.34
Accounts Payable	0.54	0.7	0.89	0.7	0.35	0.71	0.7	0.29		0.24	0.8	0.82	-0.24	0.24	0.71	0.88	0.16	0.77	0.95	0.88	0.21	0.72	0.79	0.43	0.83	0.86
Cash	0.7	0.5	0.39	0.36	0.79	0.6	0.08	0.63	0.24		0.38	0.15	0.36	1.0	0.13	0.18	0.45	0.22	0.28	0.59	0.42	0.53	0.57	0.3	0.2	0.18
Non Current Assets Total	0.74	0.71	0.75	0.6	0.58	0.92	0.62	0.6	0.8	0.38		0.56	-0.23	0.38	0.85	0.95	0.27	0.9	0.79	0.71	0.19	0.74	0.89	0.37	0.96	0.94
Non Currrent Assets Other	0.42	0.76	0.68	0.92	0.17	0.44	0.82	-0.11	0.82	0.15	0.56		-0.02	0.15	0.34	0.64	0.18	0.37	0.88	0.74	0.33	0.72	0.52	0.81	0.63	0.67
Other Assets	0.45	0.39	-0.32	0.07	0.52	-0.23	0.26	-0.35	-0.24	0.36	-0.23	-0.02		0.36	-0.19	-0.23	0.76	-0.33	-0.1	0.06	0.87	0.39	-0.34	0.22	-0.17	-0.17
Cash And Short Term Investments	0.7	0.5	0.39	0.36	0.79	0.6	0.08	0.63	0.24	1.0	0.38	0.15	0.36		0.13	0.18	0.45	0.22	0.28	0.59	0.42	0.53	0.57	0.3	0.2	0.18
Net Receivables	0.63	0.52	0.6	0.27	0.52	0.73	0.52	0.44	0.71	0.13	0.85	0.34	-0.19	0.13		0.89	0.36	0.9	0.67	0.54	0.24	0.59	0.7	0.01	0.85	0.87
Good Will	0.67	0.7	0.75	0.57	0.45	0.78	0.71	0.38	0.88	0.18	0.95	0.64	-0.23	0.18	0.89		0.29	0.93	0.84	0.71	0.22	0.74	0.79	0.31	0.98	0.98
Common Stock Shares Outstanding	0.77	0.61	0.04	0.24	0.76	0.26	0.46	-0.05	0.16	0.45	0.27	0.18	0.76	0.45	0.36	0.29		0.18	0.3	0.39	0.88	0.65	0.17	0.24	0.3	0.35
Non Current Liabilities Total	0.59	0.52	0.68	0.3	0.44	0.77	0.49	0.56	0.77	0.22	0.9	0.37	-0.33	0.22	0.9	0.93	0.18		0.66	0.61	0.07	0.59	0.78	0.01	0.9	0.85
Inventory	0.61	0.8	0.85	0.82	0.43	0.73	0.79	0.21	0.95	0.28	0.79	0.88	-0.1	0.28	0.67	0.84	0.3	0.66		0.89	0.36	0.8	0.76	0.61	0.82	0.85
Other Current Assets	0.71	0.78	0.89	0.73	0.6	0.73	0.61	0.37	0.88	0.59	0.71	0.74	0.06	0.59	0.54	0.71	0.39	0.61	0.89		0.43	0.81	0.8	0.52	0.69	0.72
Other Stockholder Equity	0.72	0.7	0.06	0.36	0.72	0.14	0.6	-0.21	0.21	0.42	0.19	0.33	0.87	0.42	0.24	0.22	0.88	0.07	0.36	0.43		0.73	0.03	0.38	0.26	0.27
Total Liab	0.9	0.99	0.6	0.76	0.74	0.65	0.88	0.17	0.72	0.53	0.74	0.72	0.39	0.53	0.59	0.74	0.65	0.59	0.8	0.81	0.73		0.59	0.63	0.78	0.75
Total Current Assets	0.64	0.56	0.86	0.58	0.54	0.95	0.36	0.75	0.79	0.57	0.89	0.52	-0.34	0.57	0.7	0.79	0.17	0.78	0.76	0.8	0.03	0.59		0.33	0.76	0.79
Short Term Debt	0.43	0.73	0.41	0.94	0.23	0.36	0.69	-0.12	0.43	0.3	0.37	0.81	0.22	0.3	0.01	0.31	0.24	0.01	0.61	0.52	0.38	0.63	0.33		0.38	0.39
Intangible Assets	0.71	0.75	0.71	0.61	0.49	0.79	0.75	0.38	0.83	0.2	0.96	0.63	-0.17	0.2	0.85	0.98	0.3	0.9	0.82	0.69	0.26	0.78	0.76	0.38		0.97
Common Stock	0.7	0.72	0.75	0.62	0.48	0.78	0.72	0.34	0.86	0.18	0.94	0.67	-0.17	0.18	0.87	0.98	0.35	0.85	0.85	0.72	0.27	0.75	0.79	0.39	0.97

Click cells to compare fundamentals

Emergent Biosolutions Account Relationship Matchups

Emergent Biosolutions fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	2.9B	3.0B	3.2B	1.8B	2.1B	1.2B
Short Long Term Debt Total	874.8M	841M	1.4B	860.2M	989.2M	1.0B
Total Stockholder Equity	1.4B	1.6B	1.4B	649.3M	746.7M	621.9M
Net Debt	253.5M	264.9M	763.2M	748.5M	860.8M	903.8M
Cash	621.3M	576.1M	642.6M	111.7M	128.5M	217.0M
Other Assets	65.6M	115M	57.3M	191.3M	220.0M	231.0M
Cash And Short Term Investments	621.3M	576.1M	642.6M	111.7M	128.5M	217.2M
Common Stock Shares Outstanding	53.8M	54.1M	50.1M	51.2M	58.9M	41.4M
Liabilities And Stockholders Equity	2.9B	3.0B	3.2B	1.8B	2.1B	1.2B
Other Current Assets	73.2M	70.4M	57.9M	47.9M	55.1M	57.8M
Other Stockholder Equity	745.3M	677.2M	645.8M	676.7M	778.2M	817.1M
Total Liab	1.4B	1.3B	1.8B	1.2B	1.3B	1.4B
Other Liab	199.9M	210.7M	156.8M	90.4M	104.0M	66.7M
Current Deferred Revenue	101.9M	131.5M	140.4M	26.4M	30.4M	28.1M
Long Term Debt	841M	809.4M	448.5M	446.5M	513.5M	290.2M
Property Plant And Equipment Gross	644.1M	800.1M	817.6M	794.2M	913.3M	959.0M
Accumulated Other Comprehensive Income	(25.3M)	(16.1M)	3.1M	(5.7M)	(5.1M)	(5.4M)
Property Plant Equipment	542.3M	644.1M	800.1M	817.6M	940.2M	987.3M
Retained Earnings Total Equity	421.8M	726.9M	957.8M	734M	844.1M	440.2M
Deferred Long Term Liab	63.9M	53.2M	94.9M	71.8M	82.6M	86.7M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Emergent Stock Analysis

When running Emergent Biosolutions' price analysis, check to measure Emergent Biosolutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emergent Biosolutions is operating at the current time. Most of Emergent Biosolutions' value examination focuses on studying past and present price action to predict the probability of Emergent Biosolutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Emergent Biosolutions' price. Additionally, you may evaluate how the addition of Emergent Biosolutions to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC